Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
about
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Anti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialNew insights into the impact of neuro-inflammation in rheumatoid arthritisConsistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab).Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION StudyWhat are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Etanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms.Skin cancer in organ transplant recipients: more than the immune system.The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.Clinical implications of shared genetics and pathogenesis in autoimmune diseases.Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximabUpdate on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report.Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's diseaseEvidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.TNF Drives Monocyte Dysfunction with Age and Results in Impaired Anti-pneumococcal Immunity.Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis.Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis.The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.Association between drug intake and incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a nested case-control study.Investigation of Cardiac Complications and their Incidence in Patients with Ankylosing Spondylitis.Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumabDevelopment of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programmeEfficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's diseaseTuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritisHepatitis B Serology in Patients with Rheumatic Diseases
P2860
Q24186403-C58DDC52-CCE3-453F-B221-B75472EEFC61Q24188040-A05B8953-C95A-4F2E-8BA0-5F7A26B27D8AQ26829488-81DA67EE-6A97-417E-B5FC-990617116D9AQ27023946-64698754-E9F2-4CE0-AA91-4030AEE0D9AAQ30377369-5A61BA79-EC87-47FC-ACE4-3E8732148073Q30679247-B903A25E-DC35-4B23-8502-9258594CEA68Q30717002-20541D1A-6E5C-4E52-B8F5-EDCC5E250175Q30799235-5E0852BB-45C4-4D5A-8999-6190E091F1B3Q30811500-A60964F4-6014-4DD9-82C3-7C497556040BQ30844786-81D140A4-878C-49EC-A6F7-877C8376A62BQ31158500-90613E33-3B45-4529-A4A4-43BF933108E5Q33725559-1F824047-9129-4390-A341-BB228A86A9DDQ33765738-D202FAE3-00B9-4978-96EE-ABA924365F18Q33804799-045D69A6-CE88-46B3-A1E1-6E23C9ADFB7CQ33923227-49F12E39-B741-4F9C-8E3A-6715731775A9Q34363241-83120E67-920A-48C7-AA52-FF1B13E33880Q34365119-A0A8D70A-C0F7-4B48-93DA-2CBE74452F92Q34658023-C41817CB-0BFA-46D6-8F52-2DBE30ECBF2AQ34818636-8E85EBAA-6DC1-4F28-8DC5-EF2F4BDF0C67Q35204309-33B51667-A89C-4A88-B441-80F390F0374BQ35535807-8855029D-6B49-420B-B951-6BC16656271FQ35559305-07CF14B7-02FD-40C5-BCD9-F471485AE95CQ35606402-AF2A7D7D-50C5-45D0-9732-064F5C129380Q35705082-7C74118D-7418-4D4D-ABB8-7CBA806913FFQ35894071-8B03D4D4-B5CB-4F94-B27F-24089E56049FQ36043446-8E93E839-9180-4BE8-8933-D8087DA7C75FQ36106183-36AD3240-6D6B-4BD0-AB6C-785DB8DF94FBQ36183786-8E262F1C-3C79-4A49-A0E8-3C91E362E9BBQ36203845-42B938D0-5E97-4E2A-8922-60DF97FD6D58Q36214720-9E774D62-7AAA-44A8-BB7A-F3B5DC949756Q36275101-E377BD6D-EE77-4CBE-A60D-6203CDC91655Q36538046-D2A0E97E-3174-4886-A775-7D59F6FBE2DCQ36654712-BD5E9E6E-2B4F-47DC-BD1E-7CA22CDAD43CQ36714237-0A7DC89E-4ABA-470E-8C5B-FB0F257BD562Q36738727-A93ADB4C-8272-4349-94C5-E65481B0F3D1Q36859619-6AEC6071-0BC5-4645-9E45-5429056BF771Q36876679-E8D7ED2A-1F92-40E9-B338-E5EA8FF19F9CQ36889586-9BE8B279-2859-4BC9-949F-2C9AA9F0E8EFQ36968737-782EB7B0-091E-4AF3-AD9A-7F0130299226Q37291847-0B2797B4-8E64-4785-BD8C-36CFF494F2A5
P2860
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Adalimumab: long-term safety i ...... psoriasis and Crohn's disease.
@ast
Adalimumab: long-term safety i ...... psoriasis and Crohn's disease.
@en
type
label
Adalimumab: long-term safety i ...... psoriasis and Crohn's disease.
@ast
Adalimumab: long-term safety i ...... psoriasis and Crohn's disease.
@en
prefLabel
Adalimumab: long-term safety i ...... psoriasis and Crohn's disease.
@ast
Adalimumab: long-term safety i ...... psoriasis and Crohn's disease.
@en
P2093
P2860
P31
P921
P1476
Adalimumab: long-term safety i ...... psoriasis and Crohn's disease.
@en
P2093
Ana P M Lacerda
Gerd R Burmester
Kenneth B Gordon
Melissa J McIlraith
Remo Panaccione
P2860
P304
P356
10.1136/ANNRHEUMDIS-2011-201244
P407
P577
2012-05-05T00:00:00Z
2013-04-01T00:00:00Z